Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 10/05/2008

    Straight questions and answers

    The 14th Biotech Finance Forum offered selected biotechnology and medical technology companies from all over Europe the opportunity of an exclusive meeting with internationally operative investors from the venture capital VC scene.

    https://www.gesundheitsindustrie-bw.de/en/article/news/straight-questions-and-answers
  • Press release - 07/05/2008 Logo ChemCon

    ChemCon – and how an ideal niche was found and occupied

    At first sight the business idea seems somehow strange Who would deliberately choose to develop and produce pharmaceutical substances that are hardly required and if so only in small quantities. Dr. Raphael Vogler and Dr. Peter Gockel the founders and owners of Freiburg-based ChemCon GmbH have done exactly that - and found an ideal niche for their company. Even the largest companies of the industry are benefiting from ChemCons know-how and…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/chemcon-and-how-an-ideal-niche-was-found-and-occupied
  • Article - 03/05/2008

    Immatics started second proof-of-concept study

    Immatics biotechnologies GmbH announced the start of a Phase III trial of its IMA910 cancer vaccine in patients with advanced colorectal cancer. The study will enroll about 70 patients in 8 European countries. The vaccine is developed to slow or halt tumor progression.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-started-second-proof-of-concept-study
  • Article - 01/05/2008

    Peter Öhlschläger - New strategies for the treatment of cancer

    Professor Peter Öhlschläger established his major scientific interests very early on. During his degree thesis at the German Cancer Research Centre DKFZ in Heidelberg the immunologist succeeded in combining his two major interests namely virology and cancer. Öhlschläger is now junior professor at the University of Constance and mainly deals with the development of therapeutic cancer vaccines.

    https://www.gesundheitsindustrie-bw.de/en/article/news/peter-hlschlaeger-new-strategies-for-the-treatment-of-cancer
  • Article - 28/04/2008 From left to right: Dr. Dr. Thomas Luft, patient Bruno Grimm, Professor Dr. Peter Dreger, Head of the Section of Allogeneic Stem Cell Transplantation.

    A milestone in the treatment of leukaemia

    Blood cancer experts in the team of Professor Peter Dreger Head of the Section of Allogeneic Stem Cell Transplantation at the University Hospital of Heidelberg have achieved a major success in the treatment of leukaemia. For the 500th time the physicians from the Department of Haematology Oncology and Rheumatology transferred blood stem cells from a healthy donor to a patient suffering from leukaemia or lymphoma.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/a-milestone-in-the-treatment-of-leukaemia
  • Article - 21/04/2008

    Human blood system in mice

    Scientists from Mannheim Heidelberg an Freiburg working together in the cooperative research area Vascular Biology have developed a method that can be used to create a human vascular system in mice which stays functional even after several months.

    https://www.gesundheitsindustrie-bw.de/en/article/news/human-blood-system-in-mice
  • Article - 20/04/2008 varionostic CEO Uwe Gerstenmaier. (Photo: varionostic GmbH)

    varionostic develops test systems for tumour markers

    The Ulm-based company varionostic GmbH has received a research grant from the German Ministry of Economics and Technology. Details on the level of the grant were not disclosed. The company will research tumour markers and develop detection systems for DNA methylations.

    https://www.gesundheitsindustrie-bw.de/en/article/news/varionostic-develops-test-systems-for-tumour-markers
  • Article - 16/04/2008

    Roland Schuele - "Research cannot be predicted"

    Professor Roland Schuele from the University Womens Hospital in Freiburg originally studied biochemistry. Nowadays Schuele is researching the development of prostate cancer. During his scientific career he has learnt that research cannot be steered in a particular direction. It develops and we follow it said Schuele who has been able to gain astonishing insights into the molecular processes in tumour cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/roland-schuele-research-cannot-be-predicted
  • Press release - 16/04/2008

    Effective Cancer Immune Therapy Through Order in the Blood Vessels

    Researchers at the German Cancer Research Center have discovered a key molecule that is responsible for the immature structure of blood vessels in malignant tumors. If this molecule is switched off in mice vessels normalize so that immune cells are better able to get to the tumor tissue.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/effective-cancer-immune-therapy-through-order-in-the-blood-vessels
  • Article - 13/04/2008 Liver tumour with vessels during the treatment with microspheres (Photo: Mannheim University Hospital)

    Selective internal radiotherapy

    Since early 2008 the Institute of Clinical Radiology and Nuclear Medicine at Mannheim University Hospital has been offering a new therapy for the treatment of liver cancers selective internal radiotherapy SIRT.

    https://www.gesundheitsindustrie-bw.de/en/article/news/selective-internal-radiotherapy
  • Article - 13/04/2008

    Scientists discover a genetic dependence to nicotine

    Scientists have shown that a particular variant of a receptor gene impacts smoking behaviour and hence confers a 30 increase in risk of lung cancer and a 20 increase in risk of peripheral artery disease PAD.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/scientists-discover-a-genetic-dependence-to-nicotine
  • Article - 05/04/2008

    Successful cooperation between science and industry (II)

    In the second article in the series on the platforms successful cooperations BioValley presents an encouraging approach for improving the quality of life of severely ill cancer patients and the successful establishment of an industrial biochip platform.

    https://www.gesundheitsindustrie-bw.de/en/article/news/successful-cooperation-between-science-and-industry-ii
  • Article - 31/03/2008 Biopharmaceuticals are not as easy to engineer as chemical substances. (Photo: ratiopharm)

    First biosimilar from Ulm close to approval

    ratiopharm Germanys second largest generics producer received a positive assessment from the EU regulatory body EMEA in London for the first filgrastim biosimilar. The company expects to receive marketing authorisation for its first biosimilar by mid to end April.

    https://www.gesundheitsindustrie-bw.de/en/article/news/first-biosimilar-from-ulm-close-to-approval
  • Article - 31/03/2008

    "Nanomedicine will be able to combat incurable diseases"

    The first European Conference for Clinical Nanomedicine is to be held soon in Basel. BIOPRO has therefore discussed this promising area of application with Beat Löffler and Dr. Patrick Hunziker the founders of the European Foundation for Clinical Nanomedicine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/nanomedicine-will-be-able-to-combat-incurable-diseases
  • Article - 25/03/2008

    A real milestone

    Somatic cell nuclear transfer or reprogramming of somatic cells into a near embryonic state - it is now expected that stem cell experts rate their findings in the field of stem cell research. What can be called a breakthrough? What is the scientific value?

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-real-milestone
  • Article - 16/03/2008 Logo apogenix

    New indication for lead compound of Apogenix

    Isolated tumour cells use to invade healthy brain tissue during the development and growth of glioblastoma multiforme GBM. This mechanism involves the CD95CD95L death system. These results supports the therapeutic potential of Apogenix APG101 for the treatment of glioblastomas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-indication-for-lead-compound-of-apogenix
  • Article - 15/03/2008

    Two Cluster of the Rhine-Neckar Metropolitan successful

    Of twelve applications which qualified for the decisive final round of the top cluster competion two are from the Rhine-Neckar metropolitan area the Forum Organic Electronics cluster and the Cell-Based Molecular Medicine biotechnology cluster.

    https://www.gesundheitsindustrie-bw.de/en/article/news/two-cluster-of-the-rhine-neckar-metropolitan-successful
  • Article - 11/03/2008

    Nils Johnsson delivers initial insights

    Nils Johnssons work focuses on communication research involving living objects. The 48-year-old biochemist is investigating how proteins manage the complicated process of cytokinesis the division of the cell plasma. Thanks to a specific method Johnsson is able to detect when proteins are interacting with each other.

    https://www.gesundheitsindustrie-bw.de/en/article/news/nils-johnsson-delivers-initial-insights
  • Article - 09/03/2008 Portrait of Dr. Anja Apel

    Successful attack on resistant tumour cells

    In laboratory experiments Dr. Anja Apel from the University Hospital in Heidelberg proved that cancer cells that are resistant to radiation therapy can be made to become susceptible to this kind of treatment again by blocking the cells own recycling system.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/successful-attack-on-resistant-tumour-cells
  • Article - 07/03/2008

    Hans-Ulrich Kauczor - expert in diagnostic radiology

    Since the 1st March 2008 the Department of Diagnostic Radiology at the University Hospital in Heidelberg has a new medical director Professor Dr. Hans-Ulrich Kauczor 45 succeeds Professor Dr. Günter Kauffmann.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hans-ulrich-kauczor-expert-in-diagnostic-radiology
  • Article - 02/03/2008

    Miniature device offers great opportunities

    The Dietmar Hopp Foundation has donated one million euro for a new small-animal tomograph at the University Hospital in Heidelberg. The new system is suitable for small animals such as rats and mice and can be used to investigate diseases and therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/miniature-device-offers-great-opportunities
  • Article - 28/02/2008

    Gilbert Gorr - a great fan of the moss Physcomitrella patens

    Dr. Gilbert Gorr has been fascinated by the moss Physcomitrella patens for many years in fact it occupies a great deal of his waking moments. The enthusiasm with which the CSO of greenovation Biotech GmbH talks about the key object of his work is both intoxicating and contagious. The latest discovery The moss produces a therapeutic antibody that is far more effective than its predecessors created in animal cell cultures.

    https://www.gesundheitsindustrie-bw.de/en/article/news/gilbert-gorr-a-great-fan-of-the-moss-physcomitrella-patens
  • Article - 16/02/2008

    Haemochromatosis is a disease of the liver

    Haemochromatosis is not as has been previously assumed a disease of the small intestine but a disease of the liver. Scientists from Heidelberg have shown in the animal model that the disease is caused by a mutated gene influencing hepcidin production.

    https://www.gesundheitsindustrie-bw.de/en/article/news/haemochromatosis-is-a-disease-of-the-liver
  • Article - 16/02/2008

    New test for the early diagnosis of cervical cancer

    mtm laboratories has launched the Cervatec assay for the early diagnosis of cervical cancer. The Cervatec assay will initially be commercialized as an adjunct to the Pap test for the screening of women aged 35 and younger.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-test-for-the-early-diagnosis-of-cervical-cancer
  • Article - 10/02/2008 DAccepted the invitation to come to Reutlingen and talk about biomarkers (from left to right) - Mike Spain, Hanno Langen, Thomas Caskey, Larry Gold, Oliver Poetz, Thomas Joos und Hans Berger (Photo: NMI)

    4th Biomarker Workshop at the NMI in Reutlingen: another success

    The Biomarker Workshop held at the NMI in late January has become a fixed date for a growing number of proteomics researchers. With an attendance of 130 this years workshop exceeded all previous ones. Those who were keen to find out more about the latest trends and findings were presented with a successful mix of basic and applied research information.

    https://www.gesundheitsindustrie-bw.de/en/article/news/4th-biomarker-workshop-at-the-nmi-in-reutlingen-another-success

Page 29 / 30

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search